title: Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen.
authors.forename: Roberta
authors.initials: R
authors.lastname: Ferraldeschi
authors.forename: Sacha J
authors.initials: SJ
authors.lastname: Howell
authors.forename: Alastair M
authors.initials: AM
authors.lastname: Thompson
authors.forename: William G
authors.initials: WG
authors.lastname: Newman
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000378:metabolism / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D018567:Breast Neoplasms, Male / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D018572:Disease-Free Survival; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence; D009364:Neoplasm Recurrence, Local; D018570:Risk Assessment; D012307:Risk Factors; D013629:Tamoxifen / Q000378:metabolism / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D004791:Enzyme Inhibitors; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6